MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Actinium Pharmaceuticals Inc

Suletud

1.39 -2.8

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.37

Max

1.43

Põhinäitajad

By Trading Economics

Sissetulek

-9.3M

-16M

Töötajad

31

EBITDA

-9.3M

-17M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+316.67% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-4.7M

44M

Eelmine avamishind

4.19

Eelmine sulgemishind

1.39

Actinium Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. juuli 2025, 23:55 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6. juuli 2025, 22:35 UTC

Omandamised, ülevõtmised, äriostud

South32 Expects to Complete Transaction in Late 2025

6. juuli 2025, 22:35 UTC

Omandamised, ülevõtmised, äriostud

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6. juuli 2025, 22:34 UTC

Omandamised, ülevõtmised, äriostud

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5. juuli 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. juuli 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4. juuli 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4. juuli 2025, 15:49 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4. juuli 2025, 15:49 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4. juuli 2025, 15:49 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Received All Required Authorizations

4. juuli 2025, 15:48 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4. juuli 2025, 15:47 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: Agreement Was Announced on Dec. 19

4. juuli 2025, 15:47 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4. juuli 2025, 15:46 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4. juuli 2025, 14:30 UTC

Omandamised, ülevõtmised, äriostud

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4. juuli 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4. juuli 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4. juuli 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4. juuli 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. juuli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4. juuli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Võrdlus sarnastega

Hinnamuutus

Actinium Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

316.67% tõus

12 kuu keskmine prognoos

Keskmine 6 USD  316.67%

Kõrge 9 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Actinium Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.